USFDA approves Teva Pharma generic Saxenda for weight loss

Parsippany: Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd., has announced the FDA approval and U.S. launch of a generic version of Saxenda (liraglutide injection). “With this approval, and by launching a generic for Saxenda (liraglutide injection), we will provide patients in the U.S. the first ever generic GLP-1 product specifically indicated for weight loss,” said Ernie Richardsen, SVP, Head of U.S. Commercial Generics at Teva. “This is the fifth first-to-market entry of a Teva generic this year and is an important addition to Teva's diverse complex generics portfolio, demonstrating once again our proven ability to sustain a world class Generics Powerhouse.” Saxenda had annual sales of $165 million as of June 2025. Liraglutide Injection is a glucagon like peptide 1 (GLP-1) receptor agonist indicated in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in: Adults and pediatric patients aged 12 years and older with body weight greater than 60 kg and obesity. Adults with overweight in the presence of at least one weight-related comorbid condition. Liraglutide injection should be used with a reduced calorie diet and increased physical activity. Liraglutide injection is not recommended for people who also take liraglutide or other medicines called glucagon-like peptide-1 (GLP-1) receptor agonists. It is not known if liraglutide injection is safe and effective in children under 12 years of age. It is not known if liraglutide injection is safe and effective in children aged 12 to 17 years with type 2 diabetes. Read also: Teva Pharma announces USFDA filing acceptance for Ajovy in Pediatric Episodic Migraine prevention